Advertisement
Screener

IGC PHARMA, INC. (IGC) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value

1.7 / 5 stars · 29/85 Roast Me

IGC PHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value

IGC PHARMA, INC. (IGC) had Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value of $0.64 per share as of 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue · last filed 2026-08-14

  • 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $0.64.
  • 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $0.68.
  • 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $0.62.
  • 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $0.61.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair ValueShare-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value as first filed
2026-06-30$0.64
10-Q · filed 2026-08-14
2026-03-31$0.68
10-Q · filed 2026-05-15
2025-12-31$0.62
10-Q · filed 2026-08-14
2025-09-30$0.61
10-Q · filed 2025-11-14
2025-06-30$0.60
10-Q · filed 2025-08-14
2025-03-31$0.61
10-KT · filed 2026-03-18
$0.64
10-K · filed 2025-06-27
2024-12-31$0.61
10-Q · filed 2025-02-14
2024-09-30$0.61
10-Q · filed 2024-11-12
2024-06-30$0.61
10-Q · filed 2024-08-07
2024-03-31$0.61
10-K · filed 2025-06-27
2023-12-31$0.65
10-Q · filed 2024-02-14
2023-09-30$0.65
10-Q · filed 2023-11-09
2023-06-30$0.65
10-Q · filed 2023-08-10
2023-03-31$1.01
10-K · filed 2024-06-24
2022-12-31$0.98
10-Q · filed 2023-02-14
2022-09-30$0.98
10-Q · filed 2022-11-01
2022-06-30$0.98
10-Q · filed 2022-08-05
2022-03-31$1.17
10-K · filed 2023-07-07
2021-12-31$1.19
10-Q · filed 2022-02-10
2021-09-30$1.35
10-Q · filed 2021-10-29
2021-06-30$0.85
10-Q · filed 2021-08-11
2021-03-31$0.85
10-K · filed 2022-06-23
2020-12-31$0.42
10-Q · filed 2021-02-16
2020-09-30$0.42
10-Q · filed 2020-11-20
2020-06-30$0.40
10-Q · filed 2020-08-19
2020-03-31$0.40
10-K · filed 2021-06-14
2019-03-31$0.45
10-K · filed 2020-07-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
Hepion Pharmaceuticals, Inc. (HEPA)United States$0.029B-0.62
Transcode Therapeutics, Inc. (RNAZ)United States$0.029B-0.12
KYNTRA BIO, INC. (KYNB)United States$0.028B0.17
BeyondSpring Inc. (BYSI)United States$0.031B-10.95
NANOVIRICIDES, INC. (NNVC)United States$0.031B
CHINA PHARMA HOLDINGS, INC. (CPHI)$0.032B
Propanc Biopharma, Inc. (PPCB)$0.032B-0.13
AYTU BIOPHARMA, INC (AYTU)United States$0.025B-1.62
Context Therapeutics Inc. (CNTX)United States$0.034B-1.10
NextCure, Inc. (NXTC)United States$0.024B-0.15